-
Kizdar net |
Kizdar net |
Кыздар Нет
Positive and clinically meaningful results from the Phase III KALOS …
Feb 13, 2026 · Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate …
AstraZeneca Pharmaceuticals LP (via Public) / BREZTRI approved in …
Apr 28, 2026 · Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: "As the fastest …
Open-label study to assess reduction of background asthma …
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce …
Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
May 2, 2025 · Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “We are excited by the positive …
BREZTRI approved in the US for asthma as first and only triple …
Apr 28, 2026 · Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “As the fastest …
One-year clinical remission with tezepelumab in severe asthma: …
Dec 16, 2025 · The Tezepelumab-induced Clinical Remission in Severe Asthma (TERESA) study is a multicenter, prospective, single …
Open-label Study to Assess Reduction of Background Asthma …
Jun 15, 2026 · Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and …
Clinical response and on-treatment clinical remission with …
The proportions of patients receiving tezepelumab who responded to treatment and who achieved on-treatment clinical remission …
Oral corticosteroid reduction and discontinuation in adults with ...
Nov 26, 2025 · Here, we report the primary results of WAYFINDER (NCT05274815), a single-arm study, which aimed to further …
Current data on biologics: Evaluating clinical remission in asthma
Sep 1, 2025 · Prospective studies in patients of all ages are needed to refine the definition of clinical asthma remission and identify …
Skip to content
Accessibility Feedback